Global Heparin Market – Industry Trends and Forecast to 2030

Heparin Market Analysis and Size

Rising prevalence of pulmonary embolism and venous thromboembolism is leading to the rise in the global heparin market value. The rising number of accidents and medical surgeries is the root cause for the rise in demand for heparin.  Also, rising disorders such as cardiovascular disorders will multiply the demand for heparin. A rise in the expenditure to improve healthcare infrastructure coupled with rising patient awareness is also expected to boost up the market demand. Research and development proficiencies will too foster the market growth rate. Furthermore, the rise in reagent rental business and emerging economies extend profitable opportunities to the market players in the forecast period of 2023 to 2030.

Stringent governmental regulations on the approval process will derail the market growth rate. The rise in competition will further pose a big challenge for the market growth in the long run. Side effects of heparin will also enable the patients to refrain from using it onto themselves.

Data Bridge Market Research analyses that the global heparin market which was USD 7.42 billion in 2022, is expected to reach USD 10.93 billion by 2030, and is expected to undergo a CAGR of 5.05% during the forecast period of 2023 to 2030.“Hospitals” dominates the end user segment of the global heparin market owing to the growing demand for drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Heparin Market Scope and Segmentation

Market Definition

Heparin is an injectable anticoagulant that is especially used in surgical procedures to prevent blood clotting in the veins and arteries.  Otherwise, it is also used to treat blood clotting disorders. It is also used to treat and diagnose pulmonary embolism, venous thromboembolism and arterial thromboembolism. Heparin is also commonly known as unfractionated heparin. Heparin is an animal-derived product, derived from the tissues of slaughtered meat.

Global Heparin Market Dynamics

Drivers

• Increasing  Prevalence of Cardiovascular Diseases

 The cases of chronic blood diseases are growing exponentially and will likely drive the worldwide antiplatelet drugs market. Increase in the prevalence of chronic diseases such as cardiovascular diseases is owing to drive the market. The rising incidences of cardiovascular diseases is a major factor driving the antiplatelet drugs market's growth rate. In both developed and developing economies, cardiovascular illnesses are the leading cause of death.

According to the Centers for Disease Control and Prevention (CDC), over 8,00,000 individuals in the United States die each year from stroke and other cardiovascular disorders.

For instance, a study by the World Health Organization (WHO) has stated that cardiovascular diseases (CVDs) account for about 31% of all patient mortality each year

• Increasing Investment for Healthcare Infrastructure

Another significant factor influencing the growth rate of global heparin market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness myriad fungal infections will expand the global herparin market. In addition, high disposable income and sedentary lifestyle of people will result in the expansion of the global herparin market. Along with this, rising geriatric population and surge in thrombotic events will enhance the market's growth rate.

• Rising Number of Geriatric Population

Expanding geriatric population worldwide is predicted to favour heparin drugs demand as this population is more prone to heart diseases. The number of persons above 65 years is projected to double in the coming years. The old age people are prone to various chronic diseases such as cardiovascular diseases, which can foster the demand for herparin drugs across the globe.

According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 and this number is expected 2.1 billion by 2050.

Opportunity

• Increase in the number of Research and Development Activities      

Rising clinical trials and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Moreover, the market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global heparin market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.

The rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the global heparin market during the forecast period.

Restraints/Challenges

• High Cost Associated

On the other hand, the high cost associated with the herparin drugs are expected to obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and limitations in safety, efficacy and tolerability of some herparin drugs will challenge the global herparin market. Moreover, the availability of counterfeit drugs and side effects linked with antiplatelet drugs is expected to restrain and further impede the growth rate of market during the forecast period in the forecast period of 2023-2030.

This global heparin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global heparin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In January 2022, Ohio-based biotechnology company Optimvia Pharmaceuticals claimed to have developed a synthetic method for creating large quantities of heparin, which is needed to make a common blood thinner, at a reasonable prices
• In February 2022, Techdow USA announced that the company has launched Heparin Sodium Injection in the United States market. This results in expanding the product portfolio and pipeline of the company to better serve customer and patient needs.

Global Heparin Market Scope

The global heparin market is segmented on the product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Unfractionated Heparin
• Low Molecular Weight Heparin (LMWH)
• Ultra-Low Molecular Weight Heparin (ULMWH)

Mode of Administration

• Oral Administration
• Parenteral  Administration

Source

• Bovine
• Porcine

Ingredient

• Sodium
• Calcium
• Others

Availability

• Raw
• Processed

Treatment

• Deep Vein Thrombosis
• Pulmonary Embolism
• Arterial Thromboembolism
• Others

Application

• Pre-Surgical Procedures
• Post-Surgical Procedures
• Kidney Dialysis
• Diagnostic Tests
• Others

Therapeutics

• Cardiovascular
• Respiratory
• Oncology
• Nephrology
• CNS
• Others

Strength

• 10 Unit
• 100 Unit
• 1000 Unit
•  5000 Unit
• 10000 Unit
• 25000 Unit
• Others

Type

• Generics
• Brands

Container

• Bottles
• Bags
• Vials
• Others

Packaging

• Glass
• Plastic

End User

• Hospitals
• Clinics
• Homecare
• Ambulatory Surgical Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy and Drug Store
• Online Pharmacy
• Others

Global Heparin Market Regional Analysis/Insights

The global heparin market is analysed and market size insights and trends are provided by product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end user and distribution channel.as referenced above.

The countries covered in the global heparin market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.   

North America dominates the global heparin market due to growing adoption of newer technologies and increasing demand for diseases-specific treatment. Additionally, the growing presence of major key players and rising healthcare expenditure will further propel the market's growth rate within region.

Europe is expected to grow in the global herparin market during the forecast period due to the surging number of cardiovascular cases and rising government initiatives in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The global heparin market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global heparin market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global heparin market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Heparin Market Share Analysis

The global heparin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global heparin market.

Some of the major players operating in the global heparin market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• OPOCRIN S.P.A. (Italy), Baxter. (U.S.)
• Aspen Holdings (South Africa)
•  B. Braun Medical Inc. (U.S.)
• Pfizer Inc. (U.S.)
• GSK plc. (U.K.)
•  LEO Pharma (Denmark)
• Sanofi (France)
• Fresenius SE & Co. KGaA (Germany)
• Changzhaou Qianhong Bio-pharma Co., ltd., (China)
• Eisai Co., Ltd. (Japan)
• Hikma Pharmaceuticals PLC. (U.K.)
• Nanjing Jianyou Biochemical Pharmaceutical Co. (China)
• Novartis AG (Switzerland)
• Shanghai Fosun Pharmaceutical (Group)Co., Ltd. (China)

SKU-34944